Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(02): 81-86
DOI: 10.1055/s-0041-1731600
Original Article: Hepatobiliary Cancer

Transarterial Radioembolization (TARE) with 131Iodine-Lipiodol for Unresectable Primary Hepatocellular Carcinoma: Experience from a Tertiary Care Center in India

Aakash Patel
1   Department of Interventional Radiology, HCG Hospital, Bangalore, Karnataka, India
,
Indusekhara Subbanna
1   Department of Interventional Radiology, HCG Hospital, Bangalore, Karnataka, India
,
Vidya Bhargavi
1   Department of Interventional Radiology, HCG Hospital, Bangalore, Karnataka, India
,
Shivakumar Swamy
1   Department of Interventional Radiology, HCG Hospital, Bangalore, Karnataka, India
,
Kumarswamy G. Kallur
2   Department of Nuclear Medicine, HCG Hospital, Bangalore, Karnataka, India
,
Shekhar Patil
3   Department of Medical Oncology, HCG Hospital, Bangalore, Karnataka, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Purpose This article presents our experience regarding survival benefits in inoperable intermediate stage hepatocellular carcinoma (HCC) and advanced stage HCC treated with 131I-lipiodol.

Materials and Methods This is a retrospective study of intermediate stage HCC (Barcelona Clinic Liver Cancer [BCLC] stage B) not responding to prior treatment and/or advanced stage HCC (BCLC stage C) treated with 131I-lipiodol. 131I-lipiodol was injected into the hepatic artery through transfemoral route. Postprocedure, the patient was isolated for 5 to 7 days. All patients underwent tumor response evaluation after 4 weeks. Survival of patients was calculated up to either death or conclusion of the study.

Results A total of 55 patients (52 males [94.5%], 3 females [5.4%]) were given intra-arterial 131I-lipiodol therapy. The median overall survival after transarterial radioembolization (TARE) was 172 ± 47 days (95% confidence limit, 79–264 days). The overall survival at 3, 6, 9, and 12 months was 69, 47, 32, and 29%, respectively. A multivariate Cox regression analysis showed the presence of treatment prior to TARE to most significantly influence survival (B = 2.161, p ≤ 0.001). This was followed by size of the lesion which was second in line (B = 0.536, p = 0.034). Among 45 patients, 14 patients (31.1%) showed a partial response, 11 patients (24.4%) showed stable disease, and 20 patients (44.4%) showed progressive diseases.

Conclusion TARE with 131I-lipiodol can be a safe and effective palliative treatment in advanced stage HCC and in patients with poor response to prior treatments like transarterial chemoembolization.

Keywords

HCC - hepatocellular carcinoma - iodine-131-lipiodol - neoplasm - transarterial radioembolization


Publication History

Article published online:
04 September 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Bruix J, Sherman M, Llovet JM. et al. EASL panel of experts on HCC: clinical management of hepatocellular carcinoma. Conclusions of the Barcelona EASL conference. European Association for the Study of Liver. J Hepatol 2001; 35: 421-430
    CrossrefPubMedGoogle Scholar
  • 2 Kumar A, Acharya SK, Singh SP. et al. (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) consensus on prevention, diagnosis and management of hepatocellular carcinoma in India: the Puri recommendations. J Clin Exp Hepatol 2014; 4 (Suppl. 03) S3-S26
    CrossrefPubMedGoogle Scholar
  • 3 Kumar A, Acharya SK, Singh SP. et al. INASL Task-Force on Hepatocellular Carcinoma. 2019 update of Indian National Association for Study of the Liver consensus on prevention, diagnosis, and management of hepatocellular carcinoma in India: the Puri II recommendations. J Clin Exp Hepatol 2020; 10 (01) 43-80
    CrossrefPubMedGoogle Scholar
  • 4 Khobragade K, Kanetkar A, Kurunkar S, Patkar S, Goel M. Five hundred oncological liver resections: single centre experience from Tata Memorial Hospital, Mumbai. HPB (Oxford) 2018; 20: S387
    CrossrefGoogle Scholar
  • 5 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 (9399) 1907-1917
    CrossrefPubMedGoogle Scholar
  • 6 Paul SB, Gamanagatti S, Sreenivas V. et al. Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: experience from a tertiary care centre in India. Indian J Radiol Imaging 2011; 21 (02) 113-120
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Saini G. Stereotactic body radiation therapy in hepatocellular carcinoma. Indian J Med Paediatr Oncol 2020; 41: 488-491
    Article in Thieme ConnectGoogle Scholar
  • 8 Culleton S, Jiang H, Haddad CR. et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014; 111 (03) 412-417
    CrossrefPubMedGoogle Scholar
  • 9 Lobo L, Yakoub D, Picado O. et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Intervent Radiol 2016; 39 (11) 1580-1588
    CrossrefPubMedGoogle Scholar
  • 10 Paul SB, Manjunatha YC, Acharya SK. Palliative treatment in advanced hepatocellular carcinoma: has it made any difference?. Trop Gastroenterol 2009; 30 (03) 125-134
    PubMedGoogle Scholar
  • 11 Lau WY. Radiotherapy with emphasis on radioembolization for liver tumors. In: Blumgart LH, Fong Y, eds. Surgery of the Liver and Biliary Tract. 2nd ed. London: W. B. Saunders London 2000: 1545-1564
  • 12 Boucher E, Garin E, Guylligomarc’h A, Olivié D, Boudjema K, Raoul J-L. Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma. Radiother Oncol 2007; 82 (01) 76-82
    CrossrefPubMedGoogle Scholar
  • 13 Kanhere HA, Leopardi LN, Fischer L, Kitchener MI, Maddern GJ. Treatment of unresectable hepatocellular carcinoma with radiolabelled lipiodol. ANZ J Surg 2008; 78 (05) 371-376
    CrossrefPubMedGoogle Scholar
  • 14 Borbath I, Lhommel R, Bittich L. et al. 131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17 (09) 905-910
    CrossrefPubMedGoogle Scholar
  • 15 Salem R, Lewandowski RJ, Mulcahy MF. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
    CrossrefPubMedGoogle Scholar
  • 16 Bhangoo MS, Karnani DR, Hein PN. et al. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol 2015; 6 (05) 469-478
    PubMedGoogle Scholar